5-Amino-1MQ
A membrane-permeable NNMT inhibitor studied in obese mouse models for NAD+/metabolic and adipose research, usually handled as an oral research solid.
What 5-Amino-1MQ is
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide chain. It appears on peptide-education sites because the same research audiences shop metabolic compounds together, but chemically it is a methylquinolinium tool compound.
Peer-reviewed work is primarily preclinical. In diet-induced obese mice, NNMT inhibition with 5-Amino-1MQ reduced adiposity and altered metabolic markers without requiring reduced food intake in key experiments. Follow-up studies combined NNMT inhibition with dietary change and examined microbiome and fat-mass endpoints.
There are no robust published human clinical dosage trials on PubMed comparable to approved metabolic drugs. Online capsule strengths are commercial research-chemical practices, not validated therapeutic regimens. Frame everything as laboratory reference information.
Nearly all of the published work on 5-Amino-1MQ is preclinical: animal models and cell studies. Human evidence is thinner than the volume of online discussion suggests.
How it works
NNMT methylates nicotinamide to 1-methylnicotinamide, influencing the NAD+ salvage pathway and methyl-donor balance. Inhibiting NNMT can raise NAD+ and SAM-related metabolic tone in adipose and other tissues in experimental systems. 5-Amino-1MQ is described as membrane-permeable and relatively selective versus several related methyltransferases, which is why it became a preferred in vivo NNMT tool compound.
Who works with it, and what they are measuring
Metabolic disease labs, adipose biologists, and NAD+-pathway chemists are the core users. Longevity and body-composition research communities amplified interest after the mouse papers, which is why dosage queries spiked despite the thin human evidence base.
What the research examines
These describe where the compound shows up in published work. None of them should be read as an established outcome.
How it appears in the literature
Amounts reported in published research, shown for reference. Not a protocol.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Diet-induced obese mouse study (Neelakantan et al.) | 20 mg | three times daily (≈60 mg/kg/day total) | subcutaneous (preclinical) |
| Follow-up DIO mouse work (Dimet-Wiley et al.) | 32 mg | once daily | subcutaneous (preclinical) |
Handling & storage
As a solid small molecule, store cool, dry, and light-protected in a tightly closed container. If a lab prepares a solution for animal work, follow solvent-specific stability (often aliquoted frozen); oral research capsules are kept sealed at controlled room temperature or per COA.
Notes on combined research
Published stacking of true interest is with dietary intervention (calorie/composition change), not with random peptide cocktails. Mechanistic neighbors include other NAD+-pathway tools (for example NMN/NR research) and separate obesity agents, but combining them is a hypothesis generator rather than a validated protocol.
5-Amino-1MQ questions
Peer-reviewed dosages are mouse doses such as 20 mg/kg SC three times daily or 32 mg/kg SC once daily. Human clinical dose-finding trials are not established in the same literature set. Commercial capsule sizes should not be confused with proven therapeutic doses.
Usually not applicable. This compound is typically an oral research solid/capsule or a solvent-dissolved animal-study preparation, not a bacteriostatic-water peptide reconstitution problem.
In mice, total daily exposure in the flagship study was on the order of 60 mg/kg/day split t.i.d. That does not translate to a responsible human daily recommendation on an education page.
A research chart should list species, route, mg/kg, and duration from primary papers. Charts that only show human capsule counts without citing clinical data overstate certainty.
Mouse pharmacokinetic profiling suggests rapid absorption and multi-hour presence above inhibitory concentrations after SC dosing; exact human half-life is not well established in peer-reviewed clinical PK papers.
The best-supported experimental 'stack' is with dietary modification in obese mouse models. Peptide stacking claims are mostly speculative and outside strong published evidence.
No. It is a small-molecule NNMT inhibitor. It is grouped with metabolic research compounds in commerce, which creates the naming confusion.
Because it is a small molecule suited to oral solid handling in research-chemical markets. Note that key efficacy papers still relied on parenteral dosing in mice due to bioavailability considerations in that species.
Read the research yourself
Verified against PubMed, one by one. A reference you cannot open is not evidence.